Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges

Bristol-Myers Squibb (NYSE: BMY) acquired its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. Under the agreement terms, Celgene shareholders will receive 1 BMY share and $50 in cash for each share of Celgene. Shares of Celgene soared more than 30% in the pre-market trading hours on Thursday, while Bristol-Myers Squibb shares plunged about … Continue reading Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges